INTREPID Alliance identifies gaps in clinical compounds targeting 12 major viral families with pandemic potential.

The INTREPID Alliance, a group of biopharmaceutical companies, has published a report highlighting gaps in the development of clinical compounds targeting 12 major viral families with pandemic potential. The second edition of the Antiviral Clinical Development Landscape lists 60 distinct direct-acting antiviral compounds, 41 of which are novel. The Alliance aims to bridge these gaps and develop treatments for identified global health threats.